By Sougato Das, President and COO, LSN

RESI San Diego was a powerhouse gathering of 300+ active early-stage life science investors including VCs, angels, family offices, CVCs, venture philanthropy, and pharma external innovation scouts across 10 distinct categories.

What made this event truly remarkable wasn’t just the sheer number of attendees, but their high level of engagement. Throughout the five-day hybrid conference, innovators and capital providers initiated thousands of high-value conversations, reinforcing why RESI remains a premier venue for early-stage companies seeking Seed, Series A, and Series B financing.

RESI San Diego: Partnering Success by the Numbers
The event saw incredible partnering activity, showcasing both high volume and improved precision:

• 11,000+ Partnering requests submitted.
• 1,400+ Accepted meetings.

This jump in efficiency reflects a growing emphasis on targeted outreach and thoughtful meeting selection, helping attendees spend less time chasing cold leads and more time speaking with organizations that closely match their technology and fundraising goals.

Furthermore, the hybrid format delivered maximum flexibility.

The RESI Differentiator: Why Our Matches are Stronger
Other industry conferences often suffer from half-empty investor profiles, making it incredibly difficult for fundraising startups to know whom to target. RESI is built differently.

• Vetted, Highly-Detailed Profiles: Our dedicated Investor Research Team manually populates and verifies every single investor profile in the system. You get the exact detail you need to determine if an investor is a legitimate fit.
• No “Undercover” Service Providers: Our team meticulously screens every participant to ensure that anyone registered as an investor is actually a legitimate capital provider ready to invest, not financial service providers in disguise.
• High Visibility on Site: With investors easily identified by their red registration badges, initiating spontaneous, high-value conversations during in-person days was easier than ever.

Maintain Your Fundraising Momentum
Fundraising is a relationship-driven process. The strongest outcomes rarely come from a single meeting; they are built through multiple touchpoints over time. Participating in sequential RESI conferences allows you to strengthen existing relationships, introduce new data milestones, and refine your pitch.

Super Early Bird registration is now open for our upcoming landmark events:

• RESI Boston (September 2026): Held during Biotech Week Boston, featuring 2 days of expanded in-person programming and 3 days of virtual partnering. (Save $300 if you register by this Friday, July 17!)
• RESI JPM 2027 (January 2027): Returning to San Francisco during JPM Healthcare Week, the busiest week in healthcare venture capital. 2 days of live networking at the SF Marriott Marquis, followed by 3 days of global virtual partnering.

Lock in the lowest rates of the season today, secure your Super Early Bird pricing, and keep your fundraising momentum moving forward!

Register for RESI Boston

Register for RESI JPM

By Sougato Das, President and COO, LSN

Raising capital is rarely about finding more investors. It’s about finding the right investors, telling the right story, and consistently building relationships that lead to meaningful opportunities. Additionally and importantly, it is about having a dedicated resource that finds those investors, reaches out to them regularly, and secures meetings with them.

Life Science Nation’s BD Assist program was created to help early-stage life science companies do exactly that by making Life Science Nation into that dedicated resource.

BD Assist is LSN’s premier business development program, providing startups with an experienced team dedicated to advancing their fundraising and partnering efforts throughout the year. Designed for companies seeking investment, licensing opportunities, or strategic collaborations, the program combines targeted investor research, strategic messaging, personalized outreach, and ongoing business development support into one comprehensive solution.

Every engagement begins by refining the company’s investment narrative and marketing materials to ensure they clearly communicate the value of the technology, market opportunity, and growth strategy. From there, Life Science Nation identifies and prioritizes a highly targeted global audience of investors and strategic partners whose interests align with the company’s stage, therapeutic area, and business objectives.

With the strategy in place, LSN launches and manages a personalized outreach campaign on the company’s behalf, tracking every interaction through the client’s CRM platform. Outreach is continuously refined based on engagement, allowing companies to build momentum over time while maintaining visibility with investors and corporate partners actively seeking new opportunities.

Clients also benefit from regular strategy discussions, ongoing campaign optimization, and access to Life Science Nation’s extensive global investor ecosystem. For companies participating in RESI conferences, BD Assist extends that support by managing partnering activities and helping maximize high-value meeting opportunities throughout the event.

Unlike traditional consulting services that provide recommendations, BD Assist becomes an extension of your business development team. LSN handles the day-to-day execution so your leadership can remain focused on advancing the science, growing the business, and preparing for meaningful investor conversations.

Whether you are preparing for your first institutional raise, expanding into new markets, or pursuing strategic partnerships, BD Assist provides the expertise, infrastructure, and execution to help accelerate your fundraising journey.

If your goal is to spend less time searching for investors and more time building relationships with the right ones, BD Assist was built for you.

Ready to activate your global roadshow? Click here to fill out the LSN Labs company assessment report and we’ll be in touch with you soon.

Click Here to Fill Out the LSN Labs Company Assessment Report

By Sougato Das, President and COO, LSN

Securing investment is rarely about delivering the perfect pitch. Successful fundraising is built on understanding how investors evaluate opportunities, developing meaningful relationships, and communicating a compelling value proposition that stands up to diligence.

On Thursday, July 9, at 12:00 PM ET, Life Science Nation will bring together an outstanding panel of active life science investors for an in-depth discussion on what it takes to raise capital in today’s investment environment. The webinar will feature George Voren, VP of Founder Strategy and Operations at Curie.Bio; Yaniv Sneor, Founder of Mid Atlantic Bio Angels; Anna Crespo Puig, Investment Analyst at AdBio Partners; and Ankita Das, Senior Venture Development Associate, Therapeutics, at NLC Health Ventures. Together, they represent a diverse range of investment perspectives spanning venture creation, angel investing, venture capital, and strategic venture development.

George Voren Curie.Bio	Yaniv Sneor Mid Atlantic Bio Angels
Anna Crespo Puig AdBio Partners	Ankita Das NLC Health Ventures

Moderated by Life Science Nation, the conversation is designed to deliver actionable insights for entrepreneurs preparing to raise capital, whether they are beginning their fundraising journey or actively engaging investors.

As market conditions continue to evolve, founders are navigating an increasingly competitive fundraising landscape. This webinar will provide practical guidance on how investors are approaching new opportunities, what they expect to see in executive summaries and pitch decks, how entrepreneurs can secure productive investor meetings both inside and outside partnering conferences, and the common mistakes that can derail an otherwise promising opportunity. The panel will also discuss what founders should expect once discussions move beyond a confidentiality agreement and into deeper diligence.

Reserve your spot today and join Life Science Nation on July 9 at 12:00 PM ET for this timely discussion.

Sign Up for the Investor Webinar